Analyst Gil Blum of Needham maintained a Buy rating on Nurix Therapeutics, retaining the price target of $27.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Gil Blum’s rating is based on several positive indicators for Nurix Therapeutics. The company is poised to start pivotal studies for its drug candidate, bexobrutideg, in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) later this year. This progress is supported by Nurix’s strong financial performance, including steady revenue from partnerships, which amounted to $44 million in the second quarter of 2025, and a robust cash position exceeding $500 million.
Additionally, recent clinical data presented at the European Hematology Association (EHA) demonstrated promising results, with some patients showing improved responses over time, including one patient achieving complete remission after more than two years of treatment. The company is also preparing to initiate an open-label study for third-line CLL treatment, pending sufficient follow-up data from an ongoing Phase Ib study. These factors collectively underpin the Buy rating, reflecting confidence in Nurix’s strategic direction and potential for future growth.
In another report released today, UBS also maintained a Buy rating on the stock with a $26.00 price target.